

von BORSTEL et al.. - Appln. No. 08/460,186
September 29, 2008

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method for ~~preventing or treating~~ toxicity due to a pyrimidine nucleoside analog comprising administering to an animal a pharmaceutically effective amount of an acylated derivative of a ~~non-methylated pyrimidine nucleoside~~ uridine or cytidine.

2. (canceled)

3. (original) A method as in claim 1 wherein said toxicity is damage to hematopoietic tissue.

4. (original) A method as in claim 1 wherein said toxicity is damage to mucosal tissues.

5. (original) A method as in claim 1 wherein said pyrimidine nucleoside analog is an antineoplastic agent.

6. (original) A method as in claim 1 wherein said pyrimidine nucleoside analog is an antiviral agent.

von BORSTEL et al.. – Appln. No. 08/460,186
September 29, 2008

7. (original) A method as in claim 1 wherein said pyrimidine nucleoside analog is an antimalarial agent.

8. (original) A method as in claim 1 wherein said pyrimidine nucleoside analog is a cytotoxic analog of uridine.

9. (original) A method as in claim 1 wherein said pyrimidine nucleoside analog is a cytotoxic analog of cytidine.

10. (original) A method as in claim 1 wherein said pyrimidine nucleoside analog is an inhibitor of pyrimidine nucleotide biosynthesis.

11. (previously presented) A method as in claim 1 wherein said pyrimidine nucleoside analog is selected from the group consisting of 5-fluorouracil (5-FU), 5-FU prodrugs including Tegafur and 5'-deoxy-5-fluorouridine, 5-fluorouridine, 2'-deoxy-5-fluorouridine, prodrug derivatives of 5-fluorouridine or 2'-deoxy-5-fluorouridine, fluorocytosine, trifluoromethyl-2'-deoxyuridine, arabinosyl cytosine, prodrugs of arabinosyl cytosine, cyclocytidine, 5-aza-2'-deoxycytidine, arabinosyl 5-azacytosine, 6-azacytidine, N-phosphonoacetyl-L-aspartic acid (PALA), pyrazofurin, 6-azauridine, azaribine, thymidine, and 3-deazauridine.

12. (original) A method as in claim 1 wherein said pyrimidine nucleoside analog is selected from the group consisting of AZT, dideoxycytidine, 5-ethyl-2'-deoxyuridine, 5-

von BORSTEL et al.. - Appln. No. 08/460,186
September 29, 2008

iodo-2'-deoxyuridine, 5-bromo-2'-deoxyuridine, 5-methylamino-2'-deoxyuridine, arabinosyluracil, dideoxyuridine and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.

13. (original) A method as in claim 1 wherein said pyrimidine nucleoside analog is 5-fluoroorotate.

14. (currently amended) A method as in claim 1 wherein said acylated ~~derivative of a non-methylated pyrimidine nucleoside~~ is triacetyluridine.

15. (currently amended) A method as in claim 1 wherein said ~~acyl~~ acylated ~~derivative of a non-methylated pyrimidine nucleoside~~ is ethoxycarbonyluridine.

16. (currently amended) A method as in claim 1 wherein said acylated ~~derivative of a non-methylated pyrimidine nucleoside~~ is triacetylcytidine.

17. (canceled).

18. (currently amended) A method as in claim 1 wherein ~~said acylated derivative of a non-methylated pyrimidine nucleoside~~ is an ~~acylated derivative of uridine, deoxyuridine, or cytidine,~~ and said administering step also includes administering an inhibitor of uridine phosphorylase selected from the group consisting of benzylacyclo-uridine, benzyloxybenzylacyclo-uridine, aminomethyl-benzylacyclo-uridine,

von BORSTEL et al. - Appln. No. 08/460,186
September 29, 2008

aminomethyl-benzyloxybenzylacetylcyclo-uridine, hydroxymethyl-benzylacetyluridine, and hydroxymethyl-benzyloxybenzylacetyluridine, 2,2'-anhydro-5-ethyluridine, 5-benzyl barbiturate, 5-benzyloxybenzyl barbiturate, 5-benzyloxybenzyl-1-[(1-hydroxy-2-ethoxy)methyl] barbiturate, 5-benzyloxybenzylacetyl-1-[(1-hydroxy-2-ethoxy)methyl] barbiturate, and 5-methoxybenzylacetylacyclobarbiturate.

19. (canceled)

20. (currently amended) A method as in claim 1 wherein said acylated ~~derivative of a non-methylated pyrimidine nucleoside~~ is an acylated derivative of cytidine or deoxycytidine, and said administering step also includes administering an inhibitor of cytidine deaminase.

21. (original) A method as in claim 20 wherein said inhibitor of cytidine deaminase is selected from the group consisting of tetrahydrouridine or tetrahydro-2'-deoxyuridine.

22. (currently amended) A method as in claim 1 wherein said ~~acylated derivative of a non-methylated pyrimidine nucleoside~~ is an acylated derivative of uridine, cytidine or deoxycytidine, and said administering step also includes administering an inhibitor of nucleoside transport.

von BORSTEL et al.. – Appln. No. 08/460,186
September 29, 2008

23. (original) A method as in claim 22 wherein said inhibitor of nucleoside transport is selected from the group consisting of dipyridamole, probenecid, lidoflazine or nitrobenzylthioinosine.

24. (original) A method as in claim 1 wherein said administering step also includes administering an agent which enhances hematopoiesis.

25. (original) A method as in claim 1 wherein said administering step also includes administering a compound capable of enhancing the uptake and phosphorylation of nucleosides into cells.